FRA:Q8T'
s ROE % Range Over the Past 10 Years
Min: -4.08 Med: 10.4 Max: 13.07
Current: 10.36
During the past 7 years, OrbusNeich Medical Group Holdings's highest ROE % was 13.07%. The lowest was -4.08%. And the median was 10.40%.
FRA:Q8T's ROE % is ranked better than 75.53% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs FRA:Q8T: 10.36
OrbusNeich Medical Group Holdings (FRA:Q8T) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
OrbusNeich Medical Group Holdings ROE % Related Terms
OrbusNeich Medical Group Holdings ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, OrbusNeich Medical Group Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OrbusNeich Medical Group Holdings ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OrbusNeich Medical Group Holdings's ROE % distribution charts can be found below:
* The bar in red indicates where OrbusNeich Medical Group Holdings's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
OrbusNeich Medical Group Holdings (FRA:Q8T) has a ROE % of 10.68% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on OrbusNeich Medical Group Holdings and its competitors. This is near median its historical median of 10.40. According to the industry distribution chart, OrbusNeich Medical Group Holdings ranks #195 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 24.5%.
Is OrbusNeich Medical Group Holdings' ROE % too high?
OrbusNeich Medical Group Holdings' current ROE % of 10.68% is near median its 10-year median of 10.40. The Medical Devices & Instruments industry median ROE % is 2.40. OrbusNeich Medical Group Holdings' value of 10.68% is 345% above this industry median. Based on the distribution chart, OrbusNeich Medical Group Holdings ranks #195 out of 797 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, OrbusNeich Medical Group Holdings has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does OrbusNeich Medical Group Holdings' ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, OrbusNeich Medical Group Holdings ranks #195 out of 797 companies for ROE %. This places OrbusNeich Medical Group Holdings in the top 25% of its industry — outperforming the majority of peers. The industry median ROE % is 2.40. OrbusNeich Medical Group Holdings' value of 10.68% is 345% above this benchmark. While the company's 10-year median is 10.40 vs. the industry median of 2.40, OrbusNeich Medical Group Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.40, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OrbusNeich Medical Group Holdings's current ROE % of 10.68% is 345% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on OrbusNeich Medical Group Holdings and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OrbusNeich Medical Group Holdings's current ROE % is 10.68%, which is near median its own 10-year median of 10.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OrbusNeich Medical Group Holdings stock overvalued right now?
OrbusNeich Medical Group Holdings (FRA:Q8T) has a current ROE % of 10.68%. The stock's GF Value™ is €0.47, compared to a current price of €0.37 — trading 22.1% below its estimated fair value. The current ROE % is 10.68%, which is near median its 10-year median of 10.40 and 345% above the Medical Devices & Instruments industry median of 2.40. OrbusNeich Medical Group Holdings' overall GF Score™ is 96/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For OrbusNeich Medical Group Holdings (FRA:Q8T), the current ROE % is 10.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OrbusNeich Medical Group Holdings (FRA:Q8T) Overvalued in 2026?
Based on GuruFocus' analysis, OrbusNeich Medical Group Holdings stock appears to be undervalued.
The current stock price of €0.37 is trading 22.1% below its estimated GF Value™ of €0.47.
Key valuation signals for FRA:Q8T:
ROE %: 10.68% (near median its 10-year median of 10.40)
GF Value™: €0.47 vs. price of €0.37 (22.1% below fair value)
Industry Position: 345% above the Medical Devices & Instruments median (#195 of 797)
No single metric tells the full story. See the FRA:Q8T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OrbusNeich Medical Group Holdings Business Description
OrbusNeich Medical Group Holdings Ltd is an investment holding company. The Company principally engaged in the manufacturing, trading, sales and marketing of medical devices/instruments used for the treatment of coronary and peripheral vascular diseases. The group has only one operating segment. The company has presence in APAC, EMEA, Japan, United States, The PRC, and Others of which majority of revenue comes from APAC.
96GF Score
Get the complete analysis for FRA:Q8T
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:Q8T has been successfully added to your 
